Tissue specific expression of Myosin IC Isoforms

Neil L Sielski, Ivanna Ihnatovych, Jacob J Hagen and Wilma A Hofmann*

Abstract

Background: Myosin IC is a single headed member of the myosin superfamily that localizes to the cytoplasm and the nucleus and is implicated in a variety of processes in both compartments. We recently identified a novel isoform of myosin IC and showed that the MYOIC gene in mammalian cells encodes three isoforms (isoforms A, B, and C) that differ only in the addition of short isoform-specific N-terminal peptides. The expression pattern of the isoforms and the mechanisms of expression regulation remain unknown.

Results: To determine the expression patterns of myosin IC isoforms, we performed a comprehensive expression analysis of the two myosin IC isoforms (isoform A and B) that contain isoform-specific sequences. By immunoblotting with isoform-specific antibodies and by qRT-PCR with isoform-specific primer we demonstrate that myosin IC isoforms A and B have distinct expression patterns in mouse tissues. Specifically, we show that myosin IC isoform A is expressed in a tissue specific pattern, while myosin IC isoform B is ubiquitously expressed at comparable levels in mouse tissues.

Conclusions: The differences in the expression profile of the myosin IC isoforms indicate a tissue-specific MYOIC gene regulation and further suggest that the myosin IC isoforms, despite their high sequence homology, might have tissue-specific and isoform-specific functions.

Keywords: Myosin IC, Isoforms, Gene expression, Tissue specificity, Protein expression

Background

Myosin IC (formerly known as myosin I-β [1]) is a single headed class I myosin that localizes to the nucleus and the cytoplasm. In the cytoplasm, myosin IC has been implicated, among other processes, in lipid raft arrangements [2], transport of vesicles containing membrane proteins such as the glucose transporter [3], and in ion channel regulation in hair cells of the inner ear [4-6]. In the nucleus, myosin IC is involved in various aspects of transcription [7-10], in chromatin remodeling [11-13], and in dynamic organization of chromosomal structures [14].

Initially, it was thought that the cytoplasmic and nuclear functions of myosin IC are facilitated by two isoforms that are encoded by the MYOIC gene, known as myosin IC and nuclear myosin I (NMI) [9,15]. However, a number of recent studies showed that both isoforms can localize to the cytoplasm and the nucleus [16,17]. In addition, we recently identified a previously unknown isoform of myosin IC and demonstrated that the MYOIC gene in mammalian cells encodes three isoforms: isoform A (newly discovered [18]), B (formerly NMI [9,15]), and C (formerly known as myosin IC [19]). As shown in Figure 1, the only difference between the three isoforms are additional, short N-terminal peptide sequences of 35 and 16 amino acids that are added to isoforms A and B respectively that are derived from upstream exons [18].

Interestingly, despite the high sequence homology, initial studies on isoform localization and function indicate that the myosin IC isoforms localize to different cellular compartments and are functionally distinct [17,18]. However, the underlying factors that facilitate the functional difference between the isoforms are not fully understood. In addition to the potential functional differences between the isoforms and their distinct intracellular localizations, our previous analysis of expression of the newly identified myosin IC isoform A in tissue culture cells also indicated a potential difference in expression patterns between the isoforms [18].

Previous studies analyzing expression of total myosin IC with antibodies directed against an epitope in the C-terminal domain that is common to all myosins as well as studies analyzing protein and mRNA expression of myosin IC isoform B (NMI) in a variety of organisms and tissues demonstrated a ubiquitous and conserved expression of myosin IC [20-22]. However, our comparison of
myosin IC isoforms A and B expression in HeLa, COS-7, and NIH 3T3 cells showed that while all three cell types express myosin IC isoform B at comparable levels, isoform A was strongly expressed only in COS-7 cells but could barely be detected in NIH 3T3 and HeLa cells [18] which suggests a difference in the expression pattern of the myosin IC isoforms. Therefore, we extended our studies and present here a comprehensive analysis of the expression pattern of myosin IC isoform A and B in mouse organs and tissues.

**Results and discussion**

As shown in Figure 1, only two of the three myosin IC isoforms that are expressed by the MYOIC gene, namely isoforms A and B, contain nucleotide and amino acid sequences that are isoform-specific and thus can be detected individually [18]. To determine protein expression of the two isoforms, we performed immunoblot analysis of a panel of 33 different organs and tissues that were collected from 2-4 month old male and female C57Bl/6 mice. Protein extracts were analyzed using antibodies that recognize the individual isoforms. Figure 1 shows a schematic of the 5’ region of MYOIC, the resulting N-terminal amino acid sequences of the myosin IC isoforms, and the amino acid sequences that are recognized by the isoform-specific antibodies. The antibody that recognizes specifically myosin IC isoform A, is a monoclonal antibody that was generated using a peptide sequence that is encoded by the isoform A-specific exon –2 as immunogen [18]. The antibody that recognizes myosin IC isoform B (NMI) is a polyclonal antibody that was generated using the isoform B-specific 16 amino acid long N-terminal peptide as immunogen [9].

Probing the organ and tissue extracts with the myosin IC isoform A-specific antibody (Figure 2A and B) showed that isoform A is expressed in a tissue-specific pattern. Expression levels are high in kidney, adrenal gland, pancreas, and in a subset of adipose tissues, specifically in tissue from epididymal and retroperitoneal adipose depots. In addition, moderate levels of isoform A protein can be consistently detected with only slight variations, in protein extracts from liver, spleen, ovaries, and tissue from mesenteric, inguinal, and white subscapular adipose depots. In the remaining 22 analyzed organs and tissues isoform A protein is only present at minimal, barely detectable levels.

In contrast to the tissue-specific expression of isoform A, myosin IC isoform B protein is easily detectable in all analyzed tissues and shows only moderate variations in expression levels, with the lowest expression observed in skeletal muscle and heart and the highest expression observed in liver, thymus, and in the various adipose depot tissues (Figure 2A and C). However, it should be noted that the maximum difference in relative expression of isoform B between the analyzed tissues is only 2.3 fold while the difference in relative expression of isoform A between the various tissues is up to 22 fold (compare Figure 2B and C).

We next analyzed if this difference in expression patterns between myosin IC isoforms A and B is also observed on mRNA level. We measured mRNA expression of the isoforms by quantitative real time PCR (qRT-PCR) using isoform-specific forward primer and reverse primer that bind to a region common to both isoforms. The location of the primer is shown in Figure 3A. We found that the mRNA expression profiles of myosin IC isoforms A and B correlate to the protein expression profiles indicating that regulation of expression takes place on gene level. Comparable to the protein data, mRNA expression of myosin IC isoform A is high in kidney, adrenal gland, pancreas, and in adipose tissue from epididymal and retroperitoneal depots. In addition, moderate levels of isoform A mRNA are expressed in liver, spleen, ovaries, and adipose tissue from mesenteric, inguinal, and subscapular white fat depots. In the remaining 22 analyzed organs and tissues isoform A mRNA can barely be detected (Figure 3B).

In contrast, isoform B mRNA is expressed in all analyzed tissues with only slight variations in expression levels (Figure 3C).

In summary, we have identified and characterized a tissue-specific expression pattern of a recently identified, novel myosin IC isoform and we demonstrate that two of the myosin IC isoforms exhibit substantial differences in the expression profiles. Our data show that in contrast to the ubiquitously expressed myosin IC isoform B, the newly discovered myosin IC isoform A exhibits tissue-specific expression patterns on both, protein and mRNA levels. Previous studies analyzing the cellular distribution of the myosin IC isoforms in COS-7 cells, i.e. in a cell line that expresses all three myosin IC isoforms at high levels [18], revealed that each of the three isoforms localizes to specific cellular regions and interacts with different
binding partners [17,18] which strongly suggests isoform-specific cellular functions. Our identification of differential expression profiles further strengthens the notion that the myosin IC isoforms are functionally distinct. Future work is aimed at understanding the regulatory mechanisms that lead to tissue-specific expression of myosin IC isoform A and at identifying potential tissue-specific functions of this isoform.

**Conclusions**
The *MYOIC* gene expresses three different isoforms two of which exhibit significant differences in expression patterns. While myosin IC isoform B is ubiquitously expressed, myosin IC isoform A exhibits a tissue-specific expressed pattern that suggests tissue-specific functions of this myosin IC isoform.

**Methods**

**Antibodies**

Figure 1 shows the isoform-specific sequences that were used to generate myosin IC isoform specific antibodies. Antibodies that recognize various isoforms of myosin IC are: 1. the anti-NMI antibody is a rabbit polyclonal antibody that was raised against the 16 amino acid long N-terminal peptide of NMI, here called isoform B [9,23] (Sigma-Aldrich, St Louis, MO); 2. the myosin IC-isoform A antibody is a mouse monoclonal antibody that was raised against the myosin IC isoform A specific N-
terminal peptide and recognizes exclusively myosin IC isoform A [18]. Monoclonal antibodies to β-actin were obtained from Sigma (Sigma-Aldrich, St Louis, MO). Peroxidase-conjugated secondary anti-mouse or anti-rabbit antibodies were obtained from Jackson ImmunoResearch Laboratories (West Grove, PA).

Animals and tissue collection
Tissue was isolated from male and female C57BL/6 mice 2–4 month old. All animal work was approved by the institutional animal care and use committee (University at Buffalo; protocol # PGY58128N). For each tissue type, tissues were extracted and analyzed from at least 3 male and 3 female mice.

Immunoblot analysis
For preparation of protein extracts, tissues were homogenized by sonication at 4°C for 5–20 seconds (depending on tissue) in extraction buffer [1x PBS, 1% NP40; 5 mM EDTA; 2% SDS, 1% Na-deoxycholate, with protease

Table 1 Primer used in qRT-PCR analysis

| Gene          | Forward primer (5’-3’)     | Reverse primer (5’-3’)     |
|---------------|-----------------------------|----------------------------|
| MYOIC (isoform A) | gtagagatcgtccgtggt         | ggaccgatgtaggtataaatgagg   |
| MYOIC (isoform B) | gcggctaccgggctcg          | ggaccgatgtaggtataaatgagg   |
| GAPDH         | ggtgaagtgtcggtgaaacq       | ctgctctctggaaatgtggt       |

Figure 3 mRNA expression of myosin IC isoforms A and B in mouse tissues. A) Schematic depicting the 5’ region of the MYOIC gene and the resulting mRNA structure. The target sequence region and location of primer used for qRT-PCR to detect myosin IC isoforms A and B are indicated by arrows. B) Quantitative real-time PCR analysis of mRNAs expression levels of myosin IC isoform A normalized to GAPDH. C) Quantitative real-time PCR analysis of mRNAs expression levels of myosin IC isoform B normalized to GAPDH. Results are presented as means + standard deviation; n =3-6 (depending on tissue type).
inhibitors (Sigma-Aldrich, St Louis, MO)) followed by a 30 min incubation on a rocking platform at 4°C. The samples were then centrifuged at maximum speed in a tabletop centrifuge for 10 min at room temperature. The supernatant was used to determine protein concentration using a Bradford protein assay according to manufacturer's instructions (Bio-Rad, Hercules, CA). Equal amounts of protein extracts (40 μg) were separated by 10% SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) and transferred onto nitrocellulose membrane. After transfer, the membrane was cut following by incubation of the lower half with antibodies specific to actin while the upper half was incubated with antibodies specific to myosin IC isoform A. Immunoreactive bands were detected by enhanced chemiluminescence. After detection of isoform A, the blots were stripped and re-probed with the antibody specific to myosin IC isoform B. Densitometric analysis was performed on the selected bands based on their relative intensities using ImageJ software.

Quantitative real-time PCR (qRT-PCR)

Total RNA was isolated from mouse tissues using Trizol® reagent (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. 1 μg total RNA from each tissue sample was used to reverse transcribe into cDNA using SuperScript III reverse transcriptase and oligo dT primer according to manufacturer's instructions (Invitrogen, Carlsbad, CA). qRT-PCR was performed using the iCycler iQ Real-Time PCR Detection System (Bio-Rad, Hercules, CA) and primer pairs that are indicated below that recognize specifically myosin IC isoform A (homo sapiens: NM_033375.4; mus musculus: XM_006532429.1) and myosin IC isoform B (homo sapiens: NM_001080950.1; mus musculus: NM_001080775). For quantification, triplicates were normalized to the average of the GAPDH housekeeping gene. For verification of sequences, the qRT-PCR product were separated on a 2% agarose gel, isolated from the gel and for DNA sequencing. Table 1 shows the primer used in qRT-PCR to detect isoform-specific expression levels of myosin IC isoforms A and B (see also schematic in Figure 3A).

Abbreviations

RT-PCR: reverse transcription polymerase chain reaction; qRT-PCR: quantitative real time polymerase chain reaction; SDS-PAGE: sodium dodecyl sulfate-polyacrylamide gel electrophoresis; PBS: phosphate buffered saline; 5′ UTR: 5′ untranslated region.

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

NLS, JH, and II performed the immunoblotting experiments. NLS and JH performed the qRT-PCR experiments. II and WAH conceived the study, participated in its design and interpretation, as well as drafting the manuscript. All authors read and approved the final manuscript.

Acknowledgements

We gratefully acknowledge Tera Domaradzki for help with tissue isolation. This study was funded in part by the Department of Defense CDMRP P30 (W81XWH-12-1-0234 to WAH).

Received: 23 December 2013 Accepted: 3 March 2014
Published: 11 March 2014

References

1. Gillespie PG, Alabern JP, Bahler M, Bement WM, Berg JS, Burgess DR, Bunsdie B, Cheney RE, Corey DP, Coudrier E, de Lanerolle P, Hammer JA, Hason J, Holt JR, Hudspeth AJ, Ikeh M, Kendricks-Jones J, Kom ED, Li R, Mercer JA, Milligan RA, Moeisiter MS, Ostap EM, Petit C, Pollard TD, Sellers JR, Soldati T, Titus MA. Myosin-I nomenclature. J Cell Biol 2001, 155(5):703–704.
2. Brandstaetter H, Kendricks-Jones J, Buss F. Myo1c regulates lipid raft recycling to control cell spreading, migration and Salmonella invasion. J Cell Sci 2012, 125(Pt 8):1991–2003.
3. Bose A, Guilherme A, Robida SI, Nicoloso SM, Zhou Q, Jiang Z, Porenerfell DP, Czech MP. Glucose transporter recycling in response to insulin is facilitated by myosin Myo1c. Nature 2002, 420(6917):821–824.
4. Cyr JL, Dumont RA, Gillespie PG. Myosin-1c interacts with hair-cell receptors through its calmodulin-binding IQ domains. J Neurosci 2002, 22(7):2487–2495.
5. Bond LM, Brandstaetter H, Kendricks-Jones J, Buss F. Functional roles for myosin 1c in cellular signaling pathways. Cell Signal 2013, 25(1):229–235.
6. Barylko B, Jung G, Alabern JP. Structure, function, and regulation of myosin 1C. Acta Biochim Pol 2005, 52(3):373–380.
7. Hofmann WA, Johnson T, Klaczynski M, Fan JL, de Lanerolle P. From transcription to transport: emerging roles for nuclear myosin I. Biochem Cell Biol 2006, 84(4):418–426.
8. Hofmann WA, Vargas GM, Ramchandran R, Stoililovic L, Goodrich JA, de Lanerolle P. Nuclear myosin I is necessary for the formation of the first phosphodiester bond during transcription initiation by RNA polymerase II. J Cell Biochem 2006, 99A(1):1001–1009.
9. Pestic-Dragovich L, Stoililovic L, Phlimonienko AA, Nowak G, Ke Y, Settlage RE, Shabanowitz J, Hunt DF, Hozak P, de Lanerolle P. A myosin I isoform in the nucleus. Science 2000, 290(5509):337–341.
10. Phlimonienko W, Zhao J, Iben S, Dingova H, Kysela K, Kahle M, Zontgraf H, Hofmann WA, de Lanerolle P, Hozak P. Gruennert I. Nuclear actin and myosin I are required for RNA polymerase I transcription. Nat Cell Biol 2004, 6(12):1165–1172.
11. Percipalle P, Farrants AK. Chromatin remodelling and transcription: be-WICHed by nuclear myosin I. Curr Opin Cell Biol 2006, 18(3):267–274.
12. Percipalle P, Frompiro N, Cavetan E, Voi D, Reimer K, Kruger T, Thiyrberg J, Scheur UJ, Grunmoff L, Farrant AK. The chromatin remodelling complex WSTF-SNF2h interacts with nuclear myosin I and has a role in RNA polymerase I transcription. EMBO Rep 2006, 7(5):525–530.
13. Sanshad A, Sadeghifar F, Louvey M, Mori R, Bohm S, Al-Muzzaini B, Vintermist A, Fomproix N, Ostlund AK, Percipalle P. Nuclear myosin 1c facilitates the chromatin modifications required to activate rRNA gene transcription and cell cycle progression. PLoS Genet 2013, 9(9):e1003397.
14. Chuang CH, Carpenter AE, Fuchsova B, Johnson T, de Lanerolle P, Belmont AS. Long-range directional movement of an interphase chromosome site. Curr Biol 2006, 16(8):825–831.
15. Nowak G, Pestic-Dragovich L, Hozak P, Phlimonienko A, Simerly C, Schatten G, de Lanerolle P. Evidence for the presence of myosin I in the nucleus. J Biol Chem 1997, 272(27):17175–17181.
16. Dzjak R, Yildirim S, Kahle M, Novak P, Hnilicova J, Venit T, Hozak P. Specific nuclear localization sequence directs two myosin isoforms to the cell nucleus in calmodulin-sensitive manner. PLoS ONE 2012, 7(1):e30529.
17. Schwab RS, Ihnatovych I, Yurusz SZ, Domaradzki T, Hofmann WA: Identification of signals that facilitate isoform specific nuclear localization of myosin IC. Exp Cell Res 2013, 319(8):1111–1123.
18. Ihnatovych I, Migocka-Patrzalek M, Dukh M, Hofmann WA: Identification and characterization of a novel myosin ic isoform that localizes to the nucleus. Cytoskeleton (Hoboken) 2012, 69(6):555–565.
19. Barylko B, Wagner MC, Reizes O, Alabern JP. Purification and characterization of a mammalian myosin I. Proc Natl Acad Sci U S A 1992, 89(2):490–494.
20. Hofmann WA, Richards TA, de Lanerolle P: Ancient animal ancestry for nuclear myosin. J Cell Sci 2009, 122(Pt 5):636–643.

21. Kahle M, Pridalova J, Spacek M, Dzijak R, Hozak P: Nuclear myosin is ubiquitously expressed and evolutionary conserved in vertebrates. Histochem Cell Biol 2007, 127(2):139–148.

22. Wagner MC, Barylko B, Albanesi JP: Tissue distribution and subcellular localization of mammalian myosin I. J Cell Biol 1992, 119(1):163–170.

23. Fomproix N, Percipalle P: An actin-myosin complex on actively transcribing genes. Exp Cell Res 2004, 294(1):140–148.

doi:10.1186/1471-2121-15-8
Cite this article as: Sielski et al: Tissue specific expression of Myosin IC Isoforms. BMC Cell Biology 2014 15:8.